Search by Drug Name or NDC

    NDC 64406-0008-01 TYSABRI 300 mg/15mL Details

    TYSABRI 300 mg/15mL

    TYSABRI is a INTRAVENOUS INJECTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Biogen Inc.. The primary component is NATALIZUMAB.

    Product Information

    NDC 64406-0008
    Product ID 64406-008_c7e88fc5-9622-4d43-9af9-42f4e77c3c4f
    Associated GPIs 62405050001320
    GCN Sequence Number 058384
    GCN Sequence Number Description natalizumab VIAL 300MG/15ML INTRAVEN
    HIC3 Z2R
    HIC3 Description LEUKOCYTE ADHESION INHIB,ALPHA4-MEDIAT IGG4K MC AB
    GCN 23805
    HICL Sequence Number 026750
    HICL Sequence Number Description NATALIZUMAB
    Brand/Generic Brand
    Proprietary Name TYSABRI
    Proprietary Name Suffix n/a
    Non-Proprietary Name natalizumab
    Product Type HUMAN PRESCRIPTION DRUG
    Dosage Form INJECTION
    Route INTRAVENOUS
    Active Ingredient Strength 300
    Active Ingredient Units mg/15mL
    Substance Name NATALIZUMAB
    Labeler Name Biogen Inc.
    Pharmaceutical Class Integrin Receptor Antagonist [EPC], Integrin Receptor Antagonists [MoA]
    DEA Schedule n/a
    Marketing Category BLA
    Application Number BLA125104
    Listing Certified Through 2024-12-31

    Package

    NDC 64406-0008-01 (64406000801)

    NDC Package Code 64406-008-01
    Billing NDC 64406000801
    Package 1 VIAL, SINGLE-USE in 1 CARTON (64406-008-01) / 15 mL in 1 VIAL, SINGLE-USE
    Marketing Start Date 2004-11-23
    NDC Exclude Flag N
    Pricing Information N/A